Platelet Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Platelet stocks.

Platelet Stocks Recent News

Date Stock Title
Apr 25 SNY AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study
Apr 25 SNY Sanofi 2024 Q1 - Results - Earnings Call Presentation
Apr 25 SNY 20 Fastest Growing Health Tech Companies in the World
Apr 25 AMGN 20 Fastest Growing Health Tech Companies in the World
Apr 25 SNY Sanofi (SNY) Q1 2024 Earnings Call Transcript
Apr 25 SNY Sanofi (SNY) Q1 Earnings In Line, Sales Miss Estimates, Stock Up
Apr 25 SNY AstraZeneca Flirts With A Breakout After Cancer Drug Sales Shine; Sanofi, Bristol Stocks Diverge
Apr 25 AMGN Analysts Estimate Amgen (AMGN) to Report a Decline in Earnings: What to Look Out for
Apr 25 DCPH Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Apr 25 SNY US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst
Apr 25 SNY Sanofi Sales, Profit Beat Expectations
Apr 25 SNY UPDATE 2-Sanofi profit slips on generic competition and currency effects
Apr 25 SNY Sanofi Non-GAAP EPS of €1.78, revenue of €10.46B; reaffirms FY24 business EPS guidance
Apr 25 SNY Sanofi profit slips on generic competition and currency effects
Apr 25 SNY Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance
Apr 24 AMGN Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?
Apr 24 DCPH Deciphera Pharmaceuticals, Inc. (DCPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Apr 24 SNY What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?
Apr 24 TTOO T2 Biosystems to Report First Quarter 2024 Financial Results and Business Updates on May 6, 2024
Apr 23 SNY Sanofi reportedly lining up banks for consumer products spinoff
Platelet

Platelets, also called thrombocytes (from Greek θρόμβος, "clot" and κύτος, "cell"), are a component of blood whose function (along with the coagulation factors) is to react to bleeding from blood vessel injury by clumping, thereby initiating a blood clot. Platelets have no cell nucleus: they are fragments of cytoplasm that are derived from the megakaryocytes of the bone marrow, and then enter the circulation. Circulating unactivated platelets are biconvex discoid (lens-shaped) structures, 2–3 µm in greatest diameter. Platelets are found only in mammals, whereas in other animals (e.g. birds, amphibians) thrombocytes circulate as intact mononuclear cells.

On a stained blood smear, platelets appear as dark purple spots, about 20% the diameter of red blood cells. The smear is used to examine platelets for size, shape, qualitative number, and clumping. The ratio of platelets to red blood cells in a healthy adult ranges from 1:10 to 1:20.
One major function of platelets is to contribute to hemostasis: the process of stopping bleeding at the site of interrupted endothelium. They gather at the site and unless the interruption is physically too large, they plug the hole. First, platelets attach to substances outside the interrupted endothelium: adhesion. Second, they change shape, turn on receptors and secrete chemical messengers: activation. Third, they connect to each other through receptor bridges: aggregation. Formation of this platelet plug (primary hemostasis) is associated with activation of the coagulation cascade with resultant fibrin deposition and linking (secondary hemostasis). These processes may overlap: the spectrum is from a predominantly platelet plug, or "white clot" to a predominantly fibrin, or "red clot" or the more typical mixture. Some would add the subsequent retraction and platelet inhibition as fourth and fifth steps to the completion of the process and still others a sixth step wound repair. Platelets also participate in both innate and adaptive intravascular immune responses.
Low platelet concentration is called thrombocytopenia, and is due to either decreased production or increased destruction. Elevated platelet concentration is called thrombocytosis, and is either congenital, reactive (to cytokines), or due to unregulated production: one of the myeloproliferative neoplasms or certain other myeloid neoplasms. A disorder of platelet function is a thrombocytopathy.
Normal platelets can respond to an abnormality on the vessel wall rather than to hemorrhage, resulting in inappropriate platelet adhesion/activation and thrombosis: the formation of a clot within an intact vessel. This type of thrombosis arises by mechanisms different than those of a normal clot: namely, extending the fibrin of venous thrombosis; extending an unstable or ruptured arterial plaque, causing arterial thrombosis; and microcirculatory thrombosis. An arterial thrombus may partially obstruct blood flow, causing downstream ischemia, or may completely obstruct it, causing downstream tissue death.

Browse All Tags